Deletions of the INK4A gene occur in malignant peripheral nerve sheath tumors but not in neurofibromas

American Journal of Pathology

Volumn 155, Issue 6, 1999, Pages 1855-1860

  Kourea, Helen P ^a   Orlow, Irene ^a   Scheithauer, Bernd W ^b   Cordon Cardo, Carlos ^a   Woodruff, James M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER GENETICS; CLINICAL ARTICLE; CONTROLLED STUDY; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; HUMAN; HUMAN TISSUE; NERVE SHEATH TUMOR; NEUROFIBROMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; SOUTHERN BLOTTING;

EID: 0032763415     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65504-6     Document Type: Article

References (37)

1. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993, 366:704-707
2. INK4B is a potential effector of TGFb-induced cell cycle arrest. Nature 1994, 371:257-261
3. INK4A/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev 1994, 8:2939-2952
4. INK4. Mol Cell Biol 1995, 15:2682-2688
5. Kamb A, Gruis NA, Weaver-Feldhaus J. Qingyun L, Harshman, Tavtigian SV, Stockert E, Day RS, Johnson BE, Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994, 264:436-440
6. Quelle DE, Zindy F, Ashmun RA, Sherr CJ: Alternative reading frames of the INK4A tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995, 83:993-1000
7. Pomerantz J, Schreiber-Agus N, Liegeois N, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordon-Cardo C, De Pinho RA: The INK4A tumor suppressor gene product, p19ARF, interacts with MDM2, and neutralizes MDM2's inhibition of p53. Cell 1998: 92:713-723
8. Zhang Y, Xiong Y, Yarbrough WG: ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4A locus deletion impairs both the Rb and p53 tumor suppressor pathways. Cell 1998, 92:725-734
9. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA: Deletions of cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994, 368:753-756
10. Orlow I, Lacombe L, Hannon GJ, Serrano M, Pellicer I, Dalbagni G, Reuter VE, Zhang ZF, Beach D, Cordon-Cardo C: Deletion of p16 and p15 genes in human bladder tumors. J Natl Cancer Inst 1995, 87: 1524-1529
11. Geradts J, Wilson PA: High frequency of aberrant p16(INK4A) expression in human breast cancer. Am J Pathol 1996, 149:15-20
12. Kovar H, Jug G, Aryee DN, Zoubek A, Ambros P, Gryber B, Windhager R, Gadner H: Among genes involved in RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors. Oncogene 1997, 15: 2225-2232
13. Schneider-Stock R, Radig K, Roessner A: Loss of heterozygosity on chromosome 9q21 (p16 gene) uncommon in soft tissue sarcomas. Mol Carcinog 1997, 18:63-65
14. Orlow I, Drobnjak M, Zhang ZF, Lewis J, Woodruff JM, Brennan MF, Cordon-Cardo C: Alterations of the INK4A and INKF4B genes in adult soft tissue sarcomas. J Natl Cancer Inst 1999, 91:73-79
15. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, Clark WH Jr, Tucker MA, Dracopoli NC: Germline p16 mutations in familial melanoma. Nat Genet 1994, 8:15-21
16. Bartkova J, Lukas J, Guldberg P, Alsner J, Kirkin AF, Zeuthen J, Bartek J: The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 1996, 56:5475-5483
17. Jen J, Harper JW, Bigner SH, Papadopoulos N, Markowitz S, Wilson JK, Kinzler KW, Vogelstein B: Deletion of p16 and p15 genes in brain tumors. Cancer Res 1994, 54:6353-6358
18. Schmidt EE, Ichimura K, Reinfenberger G, Collins P: CDKN2 (p16/ MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 1994, 54:6321-6324
19. Walker DG, Duan W, Popovic EA, Kaye AH, Tomlinson FH, Lavin M: Homozygous deletions of the multiple tumor suppessor gene 1 in the progression of human astrocytomas. Cancer Res 1995, 55:20-23
20. Fueyo J, Gomez-Manzano C, Bruner JM, Saito Y, Zhang B, Zhang W, Levin VA, Yung WK, Kyritsis AP. Hypermethylation of the CpG island of p16/CDKN2A correlates with gene inactivation in gliomas. Oncogene 1996, 13:1615-1619
21. Takita J, Hayashi Y, Kohno T, Yamaguchi N, Hanada R, Yamamoto K, Yokota J: Deletion map of chromosome 9 and p16 (CDKN2A) gene alterations in neuroblastoma. Cancer Res 1997, 57:907-912
22. Woodruff JM: Pathology of major peripheral nerve sheath neoplasms Soft Tissue Tumors. Edited by Weiss SW, Brooks JSJ. Baltimore, Williams and Wilkins, 1996, pp 129-161
23. Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM: Malignant peripheral nerve sheath tumor: a clinicopatho ogic study of 120 cases. Cancer 1986, 57:2006-2021
24. Hruban RH, Shiu MH, Senie RT, Woodruff JM: Malignant peripheral nerve sheath tumors of the buttock and lower extremity: a study of 43 cases. Cancer 1990, 66:1253-1265
25. Kourea HP, Bilsky MH, Leung DH, Lewis JJ, Woodruff JM: Subdiaphragmatic and intrathoracic paraspinal malignant peripheral nerve sheath tumor: a clinicopathologic study of 25 patients and 26 tumors. Cancer 1998, 82:2191-2203
26. Menon AG, Anderson KM, Riccardi VM, Chung RY, Whaley JM, Yandell DW, Farmer GE, Freiman RN, Lee JK, Li FP, Barker DF, Ledbetter DH, Kleider A, Martuza RL, Gusella JF, Seizinger BR: Chromosome 17p deletions, and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc Natl Acad Sci USA 1990, 87:5435-5439
27. Legius E, Dierick H, Wu R, Hall BK, Marynen P, Cassiman JJ, Glover TW: TP53 mutations are frequent in malignant NF1 tumors. Genes Chromosomes Cancer 1994, 10:250-255
28. Kindblom LG, Ahlden M, Meis-Kindblom JM, Stenman G: Immunohistochemical and molecular analysis of p53, MDM2, proliferating cell nuclear antigen and Ki67 in benign and malignant nerve sheath tumors. Virchows Arch 1995, 427:19-26
29. Halling KC, Scheithauer BW, Halling A, Nascimento AG, Ziesmer SC, Roche PC, Wollan PC: p53 expression in neurofibroma, and malignant peripheral nerve sheath tumor: an immunohistochemical study of sporadic, and NF1-associated tumors. Am J Clin Pathol 1996, 106:282-288
30. Kip in malignant transformation of neurofibromas. Am J Pathol 1999, 155:1885-1891.
31. Orita M, Suzuki Y, Sekiya T, Hayashi K: Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 1989, 5:874-879
32. Zhang SY, Klein-Szanto AJ, Sauter ER, Shafarenko M, Mitsunaga S, Nobori T, Carson DA, Ridge JA, Goodrow TL: Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res 1994, 54:5050-5053
33. Chen W, Weghorst CM, Sabourin CL, Wang Y, Wang D, Bostwick DG, Stoner GD: Absence of p16/MTS1 gene mutations in human prostate cancer. Carcinogenesis 1996, 17:2603-2607
34. Sato K, Schauble B, Kleihues P, Ohgaki H: Infrequent alterations of the p15, p16, CDK4 and cyclin D1 genes in non-astrocytic human brain tumors. Int J Cancer 1996, 66:305-308
35. Castresana JS, Gomez L, Garcia-Miguel P, Queizan A, Pestana A: Mutational analysis of the p16 gene in human neuroblastomas. Mol Carcinog 1997, 18:129-133
36. Williams BO, Remington L, Albert DM, Mukai S, Bronson RT, Jacks T: Cooperative tumorigenic effects of germline mutations in Rb and p53. Nat Genet 1994, 7:480-484
37. Cordon-Cardo C, Zhang ZF, Dalbagni G, Drobinak M, Charytonowicz E, Hu SX, Xu HJ, Reuter VE, Benedict WF: Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res 1997, 57:1217-1221